Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tegobuvir

Generic Name: Tegobuvir

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₁₄F_₇N_₅

CAS Number: 1000787-75-6

Unique Ingredient Identifier: 5NOK5X389M

Overview

Tegobuvir has been investigated for the treatment of Hepatitis C, Chronic.

Background

Tegobuvir has been investigated for the treatment of Hepatitis C, Chronic.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Phase 2

Completed

Posted: 2011/09/16

Sponsor:Gilead Sciences

ID:NCT01435226

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Phase 2

Completed

Posted: 2011/09/15

Sponsor:Gilead Sciences

ID:NCT01434498

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Phase 2

Completed

Posted: 2011/05/13

Sponsor:Gilead Sciences

ID:NCT01353248

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Phase 2

Completed

Posted: 2011/01/07

Sponsor:Gilead Sciences

ID:NCT01271790

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Phase 2

Completed

Posted: 2010/10/21

Sponsor:Gilead Sciences

ID:NCT01225380

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy